AEP-IN-3 (compound 18) is an orally administered, potent asparagine endopeptidase (AEP) inhibitor that effectively crosses the blood-brain barrier. It boasts an IC50 of 7.8 ± 0.9 nM and is applicable in Alzheimer’s Disease (AD) research [1].

AEP-IN-3 (Compound 18) exhibits a bioavailability of 83% with a half-life of T 1/2 [1]. Administered orally at a dosage of 20 mg/kg twice daily with a 7-8 hour interval for five consecutive days, AEP-IN-3 showed significant inhibition of AEP activity in the brains of transgenic mice carrying human Tau 2N4R isoform with P301L mutation in the FVB/N genetic background (3.8 months old) [1]. It also reduced the formation of Tau N368 fragments, although it did not significantly affect total Tau levels [1].